Migdalia Sotir
Psychiatry · Wheaton, ILNPI 1083771539
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $772 and has fallen 82.3% since, to $136 in 2025.
Across 97 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$218
- Johnson & Johnson$197
- Corium, LLC$188
- Shire North American Group Inc$130
- Otsuka America Pharmaceutical, Inc.$117
- Takeda Pharmaceuticals U.S.A., Inc.$112
- plus $811 from 19 others
What the payments were for
- Food & beverage$1,773100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 19 | $218 |
| Johnson & Johnson | 9 | $197 |
| Corium, LLC | 8 | $188 |
| Shire North American Group Inc | 8 | $130 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $112 |
| AbbVie | 5 | $105 |
| Sunovion Pharmaceuticals Inc. | 5 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Alkermes, Inc. | 2 | $48 |
| Avanir Pharmaceuticals, Inc. | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 1 | $31 |
| Tris Pharma Inc | 2 | $30 |
| Almatica Pharma LLC | 1 | $30 |
| Neos Therapeutics, LP | 2 | $27 |
| Biogen | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $9 |
How this compares
$1,773 in reported general payments places this provider in the 80th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atomoxetine Hcl | 12 | $270 |
| Sertraline Hcl | 22 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $30 | $15222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Wheaton
- Syed AliWheaton$31K
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
- Abid NazeerOak Brook$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.